A study published in the NEJM found that Pfizer's Celebrex posed no higher risk to a patient's heart than ibuprofen or naproxen, The Wall Street Journal reported Sunday.
According to two different analyses of a 24 000-patient study, which was also presented at the annual scientific meeting of the American Heart Association, patients assigned to take Celebrex had fewer heart-related deaths, heart attacks and strokes than those assigned to either of the other drugs.
In the study, patients with either osteoarthritis or rheumatoid arthritis who needed to take NSAIDs daily to function, were given doses of drugs commonly used in medical practice.
The result of the study "is exactly opposite of what everybody thought it would be," said principal investigator Steven E. Nissen, adding that the study also did not find any evidence to support the belief that naproxen is safer for the heart than other NSAIDs.
Nissen said he considers the non-inferiority finding as "rock solid."
To read more NewsPoints articles, click here.